Serina Therapeutics, Inc. (SER): debt financing — AgeX draws $500k from secured note; Serina licenses POZ polymer tech to Pfizer

Serina Therapeutics, Inc.

AgeX drew $500k under Amended Secured Convertible Promissory Note with Juvenescence; maturity Feb 14, 2024.
Serina Therapeutics entered non-exclusive license with Pfizer for POZ polymer technology for LNP formulations.
License agreement is potential milestone for Serina, which is merging with AgeX (S-4 filed Nov 14, 2023).
AgeX's merger with Serina remains subject to stockholder and SEC approvals.

item 2.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Serina Therapeutics, Inc. incurred loan of $500,000 with Juvenescence Limited maturing February 14, 2024.

Instrument: loan
Principal: $500,000
Counterparty: Juvenescence Limited
Maturity: February 14, 2024
Event: incurrence

Exact text from the filing

On November 15, 2023, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited (“Juvenescence”).

View on SEC.gov

Browse all debt financings →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-041874

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.